医学
2型糖尿病
血糖性
随机对照试验
内科学
荟萃分析
糖尿病
2型糖尿病
达帕格列嗪
恩帕吉菲
卡格列净
置信区间
内分泌学
作者
P. Meera Khan,Shubhashree Venkatesh,Rizwana Parveen,Pinki Mishra,Seema Jain,Nidhi Agarwal
标识
DOI:10.1080/14656566.2023.2279100
摘要
Introduction Ertugliflozin, a sodium-glucose cotransporter-2 inhibitor, seems to improve glycemic control in type 2 diabetes mellitus (T2DM). We aim to evaluate the efficacy of Ertugliflozin across multiple time intervals (18, 26, and 52 weeks) in T2DM patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI